首页> 外文期刊>Diabetes care >Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial
【24h】

Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial

机译:Liraglutide与安慰剂对患有2型糖尿病患者急性胆囊或胆汁病事件的影响,该糖尿病患者心血管事件高患者随机试验

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE To explore gallbladder- and biliary tract-related events reported for the liraglutide and placebo groups in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial. RESEARCH DESIGN AND METHODS LEADER was an international, randomized, double-blind, controlled cardiovascular (CV) outcomes trial. Participants with type 2 diabetes at high risk for CV events (n = 9,340) were randomized 1:1 to receive either liraglutide (<= 1.8 mg daily; n = 4,668) or placebo (n = 4,672), with both groups also receiving standard care (treatment period: 3.5-5 years). Acute gallstone disease was a medical event of special interest. This post hoc analysis categorized captured events of acute gallbladder or biliary disease into four groups: uncomplicated gallbladder stones, complicated gallbladder stones, cholecystitis, and biliary obstruction. Time to first event by treatment group was analyzed using Cox regression. RESULTS There was an increased risk of acute gallbladder or biliary disease with liraglutide versus placebo (n = 141 of 4,668 vs. n = 88 of 4,672 patients, respectively; hazard ratio [HR] 1.60; 95% CI 1.23, 2.09; P < 0.001). Similar trends were observed for each of the four categories of gallbladder- or biliary tract-related events. Cholecystectomy was performed more frequently in liraglutide-treated patients (HR 1.56; 95% CI 1.10, 2.20; P = 0.013) but for similar proportions of the patients who experienced gallbladder- or biliary tract-related events (57% with liraglutide vs. 59% with placebo). CONCLUSIONS Although LEADER was not specifically designed to assess acute gallbladder or biliary disease, the trial showed an increased risk of gallbladder- or biliary tract-related events with liraglutide versus placebo, which appeared to be consistent across four categories of these events. Further studies should investigate the relevant mechanisms.
机译:目的探讨罗格卢德和安慰剂群落的胆囊和胆道相关事件,在林吉德效应和糖尿病中的作用中的作用:心血管结果结果(领导者)试验。研究设计和方法领导是国际,随机,双盲,受控心血管(CV)结果试验。 CV事件(n = 9,340)高风险的糖尿病的参与者被随机1:1接受黎棱镜(每日<= 1.8mg; n = 4,668)或安慰剂(n = 4,672),两组也接受标准护理(治疗期:3.5-5岁)。急性胆结石疾病是一个特别兴趣的医疗事件。该后HOC分析分类为急性胆囊或胆道疾病的捕获事件分为四组:简单的胆囊结石,复杂的胆囊结石,胆囊炎和胆管梗阻。使用COX回归分析治疗组第一次事件的时间。结果急性胆囊或胆汁疾病的风险增加,黎棱镜与安慰剂(n = 141,共4,668例,分别为4,672名患者的4,672名患者。危害比[HR] 1.60; 95%CI 1.23,2.09; P <0.001 )。对于四类胆囊或胆道相关事件中的每一个,观察到类似的趋势。胆囊切除术在黎勒胺治疗的患者中更频繁地进行(HR 1.56; 95%CI 1.10,2.20; P = 0.013),但对于经历胆囊或胆道相关事件的患者的相似比例(Liraglutide与59的57%与安慰剂的百分比)。结论虽然领导者没有专门用于评估急性胆囊或胆道疾病,但该试验表明,胆囊或胆道与黎勒德的胆道与安慰剂的风险增加,这似乎是一致的四类这些事件。进一步的研究应该调查相关机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号